Loading...
XASXIBX
Market cap2mUSD
Dec 23, Last price  
0.02AUD
1D
0.00%
1Q
-20.00%
IPO
-86.36%
Name

Imagion Biosystems Ltd

Chart & Performance

D1W1MN
XASX:IBX chart
P/E
—
P/S
2.94
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-33.49%
Rev. gr., 5y
48.17%
Revenues
1m
+188.85%
001220,102191,477410,854205,717232,865473,4291,367,477
Net income
-12m
L+27.17%
-2,514,978-4,400,945-1,034,477-7,794,602-8,347,766-5,466,185-7,795,098-8,639,207-9,809,193-12,473,916
CFO
-8m
L-4.43%
-2,430,657-4,223,809-267,256-6,977,385-8,133,975-4,182,045-4,623,090-5,068,491-8,701,010-8,315,963
Earnings
Feb 28, 2025

Profile

Imagion Biosystems Limited provides medical imaging technologies based on superparamagnetic relaxometry for cancer and disease detection, and monitoring therapy. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company develops MagSense, which is in Phase I clinical trials for the treatment of HER2 breast cancers; and PrecisionMRX, an iron oxide nanoparticle to detect cancer. Imagion Biosystems Limited has a collaborative research program with Patrys Limited to use the combined technologies for enhancing brain tumor imaging and diagnosis; and a joint development agreement with Global Cancer Technology, Inc. to develop GCT's novel nanoscintillator technology for the treatment of breast cancer. The company was incorporated in 2016 and is based in San Diego, California.
URL
https://imagionbiosystems.com/
IPO date
Jun 22, 2017
Employees
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,367
188.85%
473
103.31%
233
13.20%
Cost of revenue
20,785
12,748
9,167
Unusual Expense (Income)
NOPBT
(19,418)
(12,275)
(8,934)
NOPBT Margin
Operating Taxes
(3,534)
2
2,615
Tax Rate
NOPAT
(15,883)
(12,277)
(11,549)
Net income
(12,474)
27.17%
(9,809)
13.54%
(8,639)
10.83%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,383
3
5,505
BB yield
-22.02%
-0.41%
-276.60%
Debt
Debt current
2,796
1,041
15
Long-term debt
6,831
8,168
77
Deferred revenue
Other long-term liabilities
4
2
3
Net debt
9,400
4,763
(13,302)
Cash flow
Cash from operating activities
(8,316)
(8,701)
(5,068)
CAPEX
(190)
(507)
(219)
Cash from investing activities
(190)
(469)
(310)
Cash from financing activities
4,292
(962)
5,146
FCF
(13,150)
(16,918)
(11,210)
Balance
Cash
227
4,446
13,394
Long term investments
Excess cash
159
4,422
13,382
Stockholders' equity
(3,788)
4,677
13,305
Invested Capital
6,042
4,861
49
ROIC
ROCE
EV
Common stock shares outstanding
30,483
28,032
26,188
Price
0.36
1,379.17%
0.02
-68.42%
0.08
-47.59%
Market cap
10,822
1,508.55%
673
-66.20%
1,990
-26.51%
EV
20,221
5,435
(11,311)
EBITDA
(18,234)
(11,167)
(8,530)
EV/EBITDA
1.33
Interest
1,128
2
4
Interest/NOPBT